SunTrust Banks, Inc. set a $80.00 price target on Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) in a research note published on Sunday morning. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.
A number of other equities research analysts have also commented on the stock. ValuEngine raised shares of Agios Pharmaceuticals from a sell rating to a hold rating in a research note on Friday, September 1st. Royal Bank Of Canada initiated coverage on shares of Agios Pharmaceuticals in a research note on Thursday, September 14th. They issued an outperform rating and a $78.00 price objective on the stock. J P Morgan Chase & Co reaffirmed a buy rating and issued a $76.00 price objective on shares of Agios Pharmaceuticals in a research note on Monday, September 18th. Credit Suisse Group upped their price objective on shares of Agios Pharmaceuticals from $61.00 to $66.00 and gave the company an outperform rating in a research note on Thursday, November 2nd. Finally, Janney Montgomery Scott reaffirmed a hold rating on shares of Agios Pharmaceuticals in a research note on Tuesday, August 1st. Three analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. The stock has a consensus rating of Buy and a consensus price target of $75.70.
Shares of Agios Pharmaceuticals (NASDAQ AGIO) opened at $60.18 on Friday. Agios Pharmaceuticals has a 12 month low of $39.24 and a 12 month high of $72.73.
Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($1.59) EPS for the quarter, beating the Zacks’ consensus estimate of ($1.78) by $0.19. Agios Pharmaceuticals had a negative net margin of 679.14% and a negative return on equity of 64.54%. The company had revenue of $11.35 million for the quarter, compared to analyst estimates of $10.85 million. During the same period in the prior year, the firm posted ($1.63) EPS. The company’s quarterly revenue was up 26.4% on a year-over-year basis. research analysts expect that Agios Pharmaceuticals will post -6.59 earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: “SunTrust Banks, Inc. Analysts Give Agios Pharmaceuticals, Inc. (AGIO) a $80.00 Price Target” was reported by Stock Observer and is the property of of Stock Observer. If you are accessing this story on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright laws. The legal version of this story can be read at https://www.thestockobserver.com/2017/11/22/suntrust-banks-inc-analysts-give-agios-pharmaceuticals-inc-agio-a-80-00-price-target.html.
In other Agios Pharmaceuticals news, insider Scott Biller sold 2,146 shares of the company’s stock in a transaction on Friday, September 1st. The shares were sold at an average price of $61.99, for a total transaction of $133,030.54. Following the transaction, the insider now owns 8,410 shares in the company, valued at $521,335.90. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Lewis Clayton Jr. Cantley sold 4,000 shares of the company’s stock in a transaction on Tuesday, November 14th. The stock was sold at an average price of $60.88, for a total transaction of $243,520.00. Following the transaction, the director now owns 82,394 shares in the company, valued at approximately $5,016,146.72. The disclosure for this sale can be found here. Over the last three months, insiders have sold 178,908 shares of company stock worth $12,163,839. 10.55% of the stock is owned by insiders.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in AGIO. BlackRock Inc. raised its holdings in Agios Pharmaceuticals by 8,463.5% during the first quarter. BlackRock Inc. now owns 2,167,074 shares of the biopharmaceutical company’s stock worth $126,556,000 after buying an additional 2,141,768 shares during the last quarter. FMR LLC raised its holdings in Agios Pharmaceuticals by 14.1% during the second quarter. FMR LLC now owns 7,227,331 shares of the biopharmaceutical company’s stock worth $371,846,000 after buying an additional 895,584 shares during the last quarter. Vanguard Group Inc. raised its holdings in Agios Pharmaceuticals by 23.8% during the second quarter. Vanguard Group Inc. now owns 3,214,770 shares of the biopharmaceutical company’s stock worth $165,401,000 after buying an additional 617,379 shares during the last quarter. Alkeon Capital Management LLC acquired a new position in Agios Pharmaceuticals during the third quarter worth $30,489,000. Finally, Janus Henderson Group PLC acquired a new position in Agios Pharmaceuticals during the second quarter worth $20,423,000. Hedge funds and other institutional investors own 92.64% of the company’s stock.
Agios Pharmaceuticals Company Profile
Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.
Receive News & Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.